ScholarIQanswers from OpenAlex
National Center for Tumor Diseases
InstitutionResearch output, impact & collaborations
National Center for Tumor Diseases is a institution indexed in ScholarIQ from OpenAlex.
What is known about National Center for Tumor Diseases?
ScholarIQrecord summary
National Center for Tumor Diseases is a research organisation in Heidelberg, DE. OpenAlex records 12,680 works and 1,761,514 citations for it. 2,508 researchers list it as their most recent affiliation.
How many works does National Center for Tumor Diseases have?
ScholarIQindexed works
National Center for Tumor Diseases has 12,680 works in the ScholarIQ index. The count is the OpenAlex total, not the number of papers listed on this page.
How many citations does National Center for Tumor Diseases have?
ScholarIQcitation count
National Center for Tumor Diseases has 1,761,514 citations in the OpenAlex counts ScholarIQ stores.
How many researchers are at National Center for Tumor Diseases?
ScholarIQresearcher count
National Center for Tumor Diseases has 2,508 researchers in the ScholarIQ index.
What is the average h-index at National Center for Tumor Diseases?
ScholarIQavg h-index
National Center for Tumor Diseases has an average h-index of 79.5 in OpenAlex.
What is the ROR of National Center for Tumor Diseases?
ScholarIQror
The ROR for National Center for Tumor Diseases is on the source record.
What is the OpenAlex record for National Center for Tumor Diseases?
ScholarIQopenalex
The OpenAlex for National Center for Tumor Diseases is on the source record.
Who are the most-cited researchers behind National Center for Tumor Diseases?
ScholarIQtop researchers by citations
What are the most-cited papers on National Center for Tumor Diseases?
ScholarIQmost cited works
Analysis of FLT3-activating mutations in 979 patients with acute myelogenous leukemia: association with FAB subtypes and identification of subgroups with poor prognosis
Christian Thiede, Christine Steudel, Brigitte Mohr, Markus Schaich, Ulrike Schäkel, Uwe Platzbecker, Martin Wermke, Martin Bornhäuser, Markus Ritter, Andreas Neubauer, Gerhard Ehninger, Thomas Illmer
Azacitidine for treatment of imminent relapse in MDS or AML patients after allogeneic HSCT: results of the RELAZA trial
Uwe Platzbecker, Martin Wermke, J. Radke, Uta Oelschlaegel, Franzi Seltmann, Alexander Kiani, I-M Klut, Holger Knoth, Christoph Röllig, Johannes Schetelig, Brigitte Mohr, Xina Graehlert, Gerhard Ehninger, Martin Bornhäuser, Christian Thiede
Randomized Phase III Study of Lenalidomide Versus Placebo in RBC Transfusion-Dependent Patients With Lower-Risk Non-del(5q) Myelodysplastic Syndromes and Ineligible for or Refractory to Erythropoiesis-Stimulating Agents
Valeria Santini, António Almeida, Aristoteles Giagounidis, Stefanie Gröpper, Anna Jonášová, Norbert Vey, Ghulam J. Mufti, Rena Buckstein, Moshe Mittelman, Uwe Platzbecker, Ofer Shpilberg, Ron Ram, Consuelo del Cañizo, Norbert Gattermann, Keiya Ozawa, Alberto Risueño, Kyle J. MacBeth, Jianhua Zhong, Francis Séguy, Albert Hoenekopp, C.L. Beach, Pierre Fenaux
Phase I First-in-Human Dose Escalation Study of the oral SF3B1 modulator H3B-8800 in myeloid neoplasms
David P. Steensma, Martin Wermke, Virginia M. Klimek, Peter L. Greenberg, Patricia Font, Rami S. Komrokji, Jay Yang, Andrew M. Brunner, Hetty E. Carraway, Lionel Adès, Aref Al‐Kali, Juan Manuel Alonso‐Domínguez, Ana Alfonso Piérola, Catherine C. Coombs, H. Joachim Deeg, Ian W. Flinn, James M. Foran, Guillermo Garcia‐Manero, Michael B. Maris, Malgorzata McMasters, Jean‐Baptiste Micol, Jaime Pérez de Oteyza, Felicitas Thol, Eunice S. Wang, Justin M. Watts, Justin Taylor, Richard M. Stone, Vikram Gourineni, Alyssa J. Marino, Huilan Yao, Benoit Destenaves, Xiaobin Yuan, Kun Yu, Sara Dar, Lernik Ohanjanian, Keisuke Kuida, Jianjun Xiao, Catherine Scholz, Antonio Gualberto, Uwe Platzbecker
A novel prognostic model in elderly patients with acute myeloid leukemia: results of 909 patients entered into the prospective AML96 trial
Christoph Röllig, Christian Thiede, Martin Gramatzki, Walter E. Aulitzky, H. Bodenstein, Martin Bornhäuser, Uwe Platzbecker, Reingard Stuhlmann, Ulrich S. Schuler, Silke Soucek, Michael Krämer, Brigitte Mohr, Uta Oelschlaegel, Friedrich Stölzel, Malte von Bonin, Martin Wermke, Hannes Wandt, Gerhard Ehninger, Markus Schaich, for the Study Alliance Leukemia
How much of the research on National Center for Tumor Diseases is open access?
ScholarIQopen access share
80%OPEN ACCESS